See more : Intense Technologies Limited (INTENTECH.NS) Income Statement Analysis – Financial Results
Complete financial analysis of LegoChem Biosciences, Inc. (141080.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of LegoChem Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Zhonglu.Co.,Ltd (600818.SS) Income Statement Analysis – Financial Results
- Elango Industries Limited (ELANGO.BO) Income Statement Analysis – Financial Results
- ReTo Eco-Solutions, Inc. (RETO) Income Statement Analysis – Financial Results
- Hub Group, Inc. (HUBG) Income Statement Analysis – Financial Results
- Coeur Mining, Inc. (CDE) Income Statement Analysis – Financial Results
LegoChem Biosciences, Inc. (141080.KQ)
About LegoChem Biosciences, Inc.
LegoChem Biosciences, Inc. a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, and oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It offers its products in the forms of tablets and capsules. The Company also sells medical device and supplies. It has a research collaboration and license agreement with AMGEN for the development and commercialization of ADCs. LegoChem Biosciences, Inc. was founded in 2006 and is headquartered in Daejeon, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 34.15B | 33.41B | 32.16B | 49.39B | 57.50B | 25.24B | 22.06B | 16.66B |
| Cost of Revenue | 16.35B | 17.58B | 16.35B | 15.90B | 24.84B | 20.86B | 16.82B | 13.97B |
| Gross Profit | 17.80B | 15.83B | 15.81B | 33.49B | 32.66B | 4.38B | 5.24B | 2.68B |
| Gross Profit Ratio | 52.12% | 47.39% | 49.15% | 67.81% | 56.79% | 17.37% | 23.74% | 16.10% |
| Research & Development | 79.61B | 55.72B | 47.89B | 56.14B | 18.52B | 18.24B | 9.26B | 7.81B |
| General & Administrative | 1.15B | 745.60M | 711.14M | 653.65M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 3.97B | 1.42B | 1.15B | 1.53B | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.51B | 15.15B | 4.45B | 9.05B | 7.53B | 4.86B | 5.82B | 5.04B |
| Other Expenses | 2.50B | 442.46M | 3.13B | -3.73M | -204.88M | -285.00K | -393.00K | 0.00 |
| Operating Expenses | 98.62B | 70.87B | 52.34B | 65.19B | 26.26B | 23.09B | 15.08B | 12.85B |
| Cost & Expenses | 114.97B | 88.45B | 68.69B | 81.09B | 51.10B | 43.95B | 31.90B | 26.83B |
| Interest Income | 5.81B | 4.27B | 901.31M | 1.04B | 1.54B | 425.05M | 465.09M | 405.64M |
| Interest Expense | 528.26M | 285.75M | 68.77M | -1.20K | 25.80M | 125.75M | 1.35B | 1.07B |
| Depreciation & Amortization | 4.67B | 4.12B | 3.05B | 2.99B | 3.86B | 2.78B | 2.64B | 2.15B |
| EBITDA | -71.38B | -43.37B | -17.53B | -26.77B | 16.99B | -23.52B | -9.51B | -12.14B |
| EBITDA Ratio | -209.06% | -152.40% | -104.12% | -58.12% | 17.85% | -63.11% | -32.66% | -48.16% |
| Operating Income | -80.82B | -55.04B | -36.53B | -31.70B | 6.40B | -18.71B | -9.84B | -10.17B |
| Operating Income Ratio | -236.70% | -164.72% | -113.61% | -64.18% | 11.13% | -74.12% | -44.62% | -61.08% |
| Total Other Income/Expenses | 5.08B | 975.61M | 5.56B | 19.19B | 2.98B | -10.45B | -3.66B | -5.19B |
| Income Before Tax | -75.75B | -47.77B | -20.64B | -10.57B | 13.10B | -26.43B | -13.50B | -15.36B |
| Income Before Tax Ratio | -221.83% | -142.99% | -64.20% | -21.40% | 22.79% | -104.70% | -61.20% | -92.23% |
| Income Tax Expense | -2.04B | -2.63B | 2.87B | -1.84B | 626.01M | -354.09M | -564.30M | -636.24M |
| Net Income | -73.70B | -45.09B | -23.39B | -6.99B | 13.59B | -25.77B | -12.93B | -14.72B |
| Net Income Ratio | -215.85% | -134.96% | -72.74% | -14.14% | 23.63% | -102.10% | -58.64% | -88.41% |
| EPS | -2.60K | -1.85K | -969.59 | -307.05 | 640.57 | -1.22K | -649.86 | -780.61 |
| EPS Diluted | -2.59K | -1.85K | -969.59 | -307.05 | 565.81 | -1.22K | -649.86 | -780.61 |
| Weighted Avg Shares Out | 28.40M | 24.36M | 24.12M | 22.75M | 21.21M | 21.08M | 19.90M | 18.86M |
| Weighted Avg Shares Out (Dil) | 28.40M | 24.36M | 24.12M | 22.75M | 24.01M | 21.08M | 19.90M | 18.86M |
Source: https://incomestatements.info
Category: Stock Reports